![](https://unclineberger.org/wp-content/uploads/sites/867/2018/09/external-site.jpeg)
September 25, 2013
Prostate cancer treatment delays onset of pain and quality of life deterioration in men with metastatic prostate cancer
Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.